Viking Therapeutics, Inc. (NASDAQ:VKTX)’s main metabolic therapy candidate, VK2735, is being developed as an injectable and oral medication. Phase 3 development for the injectable version is scheduled ...
Viking Neptune godmother and retired NASA astronaut Nicole Stott (left) stands with Viking chairman Torstein Hagen and Viking executive vice president Karine Hagen. Photo Credit: Viking Using a Viking ...
Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient Secures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector Supply ...
Viking Therapeutics, Inc. (NASDAQ:VKTX) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Viking Therapeutics, Inc. (NASDAQ:VKTX) and CordenPharma have concluded a multi-year ...
SAN DIEGO, March 11, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback